Predicting portal hypertension in patients with Common Variable Immunodeficiency
Evaluation of Ultrasound Parameters and Liver and Spleen Stiffness for Prediction of Clinically Significant Portal Hypertension in Patients With Common Variable Immunodeficiency Syndrome
This study is testing ways to predict portal hypertension in people with Common Variable Immunodeficiency by doing regular check-ups and tests at the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Freiburg Academic / other |
| Locations | 1 site (Freiburg) |
| Trial ID | NCT06145100 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prediction of portal hypertension in patients diagnosed with Common Variable Immunodeficiency (CVID). During routine annual visits at the University Medical Center Freiburg, patients will undergo clinical evaluations, including abdominal ultrasound and liver stiffness measurements. The study will categorize participants into three subgroups based on their liver involvement and the presence of clinically significant portal hypertension. Additionally, serum and plasma samples will be collected for future analysis and stored in a biobank.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Common Variable Immunodeficiency.
Not a fit: Patients with concomitant chronic liver diseases or those who do not provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the early detection and management of portal hypertension in patients with CVID.
How similar studies have performed: While there is limited data on studies specifically targeting CVID and portal hypertension, similar approaches in assessing liver conditions have shown promise in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with CVID Exclusion Criteria: * no written informed consent * concomitant chronic liver disease (viral hepatitis, alcoholic liver disease, steatitic liver disease, hemochromatosis, primary biliary cholangitis, primary sclerosis cholangitis, M. Wilson, alpha-1-antitrypsin deficiency)
Where this trial is running
Freiburg
- University Medical Center Freiburg, Department of Medicine II — Freiburg, Germany (Recruiting)
Study contacts
- Principal investigator: Dominik Bettinger, MD — University Hospital Freiburg
- Study coordinator: Dominik Bettinger, MD
- Email: dominik.bettinger@uniklinik-freiburg.de
- Phone: +49761270-36870
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.